Authors
Latest:
Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Latest:
Artificial Intelligence in Cancer Care: Addressing Challenges and Health EquityArtificial intelligence may mitigate overdiagnosis and unnecessary treatments in cancer care by integrating with precision medicine.
Latest:
Cancer Pain and Opioid Use DisorderInvestigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Latest:
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckThis study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
Latest:
Kohei Shitara, MD, Discusses Immunotherapy in Gastric Cancer at 2022 IGCCKohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.
Latest:
Immunotherapy and Vaccines Inspire Hope in Glioblastoma Care“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Latest:
Karen's Advice: What Every MM Patient Should KnowPanelists discuss how patients with multiple myeloma can achieve excellent quality of life with bispecific therapies like talquetamab despite manageable adverse effects, with Karen sharing her advice to embrace treatment opportunities, accept a "new normal," and focus on the meaningful life experiences these innovative therapies enable, including her recent trip to Italy and time with 6 grandchildren she wouldn't have met without these advancing treatments.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and PhysiciansPractical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.
Latest:
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
3 Things You Should Know About Hemolytic AnemiasHemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCLAn expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
BMS-986393 Appears Effective, Safe in Relapsed/Refractory Multiple MyelomaGPRC5D may be a promising therapeutic pathway in the treatment of those with relapsed/refractory multiple myeloma, says Susan Bal, MD.
Latest:
Improving NSCLC Surgery Recovery After Climate Disaster ExposureThe “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Latest:
Ensuring Safe Bispecific Antibody Use in Lymphoma at Community PracticesHarmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Latest:
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory ArthritisThis case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.
Latest:
Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCCAt 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.
Latest:
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?Panelists discuss management strategies for a patient with low-risk myelodysplastic syndrome with erythropoiesis-stimulating agent (ESA) failure, weighing options between initiating luspatercept or escalating ESA dosage while emphasizing the need for thorough evaluation of reversible causes before advancing therapy.
Latest:
Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer SymposiumThe expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
